Credit Suisse Downgrades AcelRx Pharmaceuticals to Neutral, Lowers Price Target to $2

Credit Suisse downgrades AcelRx Pharmaceuticals (NASDAQ:ACRX) from Outperform to Neutral and lowers the price target from $7 to $2.

Benzinga · 11/11/2019 12:23

Credit Suisse downgrades AcelRx Pharmaceuticals (NASDAQ:ACRX) from Outperform to Neutral and lowers the price target from $7 to $2.